Form 4: Vertex Pharmaceuticals CEO Reshma Kewalramani Reports Stock Disposal
SEC Form 4 Filing
Reshma Kewalramani, CEO of Vertex Pharmaceuticals, disposed of 6,553 shares of common stock on February 14, 2025, to cover tax obligations.
Summary
- On February 14, 2025, Reshma Kewalramani, the CEO and President of Vertex Pharmaceuticals, disposed of 6,553 shares of common stock.
- The transaction was executed at a price of $463.46 per share.
- Following the transaction, Kewalramani directly owns 129,380 shares of Vertex Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports a stock disposal, likely for tax purposes, which is a routine transaction.
Industry Context
Form 4 filings are standard disclosures required by the SEC when corporate insiders, like the CEO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine stock disposal by an executive.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of stock disposal transaction |
| 02/19/2025 | Date of Form 4 signature |
Keywords
Form 4, VRTX, Vertex Pharmaceuticals, Reshma Kewalramani, CEO, Stock Disposal, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.